Breast cancers are generally divided into subtypes based on the presence, or lack, of receptors found within the tumor: estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). The most successful treatments for breast cancer are hormonal and targeted therapies for these receptors. Unfortunately, none of these receptors are found in women with the triple negative breast cancer (TNBC) subtype. While 20-30% of TNBC patients respond to chemotherapy treatment, TNBC patients with residual disease post-therapy have low overall survival rates. Even patients who do respond to chemotherapy treatment are likely to have recurrence and metastasis years after the initial treatment. It is therefore necessary to develop novel and improved therapies for patients with TNBC. We propose to interrogate the difference between Hippo pathway activation in chemo-sensitive and –insensitive TNBC cell lines and patient samples using our novel MIB/MS (multiplexed inhibitor beads and mass spectrometry) technology. The Hippo pathway is an evolutionary conserved regulator of tissue growth and cell fate that has been shown to be disregulated in many cancers, including breast cancer. Our studies will define kinase dynamics within the Hippo pathway that can be used to specific kinases with small molecule inhibitors to enhance the sensitivity of chemo-resistant tumors to combination therapies. Using these methods, we hope to find better treatment options for patients with TNBC.
|Effective start/end date||10/8/15 → 10/7/18|
- Susan G Komen for the Cure
Triple Negative Breast Neoplasms